Compare Smith & Nephew plc (SNN) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Smith & Nephew plc trades at $27.17 (market cap $11.10B), while iShares Broad USD Investment Grade Corporate Bond trades at $49.85 (market cap $17.53B). The key difference: iShares Broad USD Investment Grade Corporate Bond is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares Broad USD Investment Grade Corporate Bond pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| SNN | USIG | |
|---|---|---|
Market Cap | $11.10B | $17.53B |
Volume | 1,051,703 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $37.17 | $52.69 |
52-Week Low | $26.42 | $48.54 |
Typical Hold Time | 120 Days | 44 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
USIG trades at $48.68 with minimal daily movement (+0.06%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The stock faces resistance at $49 with support at $48. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake by 0.9% in Q2 2026.
The outlook remains cautious due to bearish technicals and lack of fundamental data. Investment opportunities include institutional accumulation, but risks involve market volatility and absence of recent financial disclosures. Investors should await updated earnings reports for clearer valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
